Hepatic fibrosis is a major health concern that can develop into other life-threatening pathologies, with no fully effective treatments are available to date. Ceiba is a genus of multipurpose trees with diverse therapeutic applications, including liver ailments. Prior research has also unveiled the protecting role of Ceiba plants in chemical liver injuries via a number of in vitro and in vivo tests. Due to the crucial need for alternative therapies to prevent liver damage and stop its progress, the present work evaluates the protective effects of the total extract of Ceiba chodatii Hassl. flowers and its derived fractions (I-IV) against CCl-induced chronic liver damage for the first time. The obtained results indicated the ability of C. chodatii flowers, particularly their chloroform- and ethyl acetate-soluble fractions (II and III), to alleviate liver damage in CCl-intoxicated rats via normalizing high liver injury hallmarks (e.g., ALT, AST, albumin, and total bilirubin), preventing the build-up of malondialdehyde, enhancing the antioxidant capacity of hepatocytes, mitigating aberrant histopathological changes, and reducing extracellular matrix accumulation. Further mechanistic studies showed the aptitude of C. chodatii flowers to attenuate inflammatory, fibrotic, and apoptotic responses via counteracting the production of inflammatory cytokines (e.g., IL-6 and TNF-α), reducing the levels of cleaved caspase-3, and inhibiting JAK2/STAT3 and TGF-β/Smad signaling pathways. Interestingly, the liver-protecting actions of fractions II and III were also comparable to those of silymarin (50 mg/kg). Moreover, phytochemical investigation of C. chodatii flowers led to the isolation and identification of a group of flavonoid glycosides (1-10), with good antioxidant and liver supporting properties, suggesting their potential contribution to the anti-fibrotic properties of C. chodatii. These data highlight the multi-target hepatoprotective effects of C. chodatii and its potential as an alternative source to develop natural therapeutic agents against liver fibrosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fitote.2025.106466 | DOI Listing |
Front Immunol
March 2025
Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).
View Article and Find Full Text PDFCardiovasc Endocrinol Metab
June 2025
Department of Medical Sciences, Faculty of Medicine, Qom Medical Sciences, Islamic Azad University, Qom, Iran.
Background: Statins are prescribed to manage hypercholesterolemia. While effective, these medications are associated with adverse effects, particularly myopathy. Cholesterol is essential for muscle function, and its depletion - especially by lipophilic statins - may contribute to muscle damage.
View Article and Find Full Text PDFCureus
February 2025
Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND.
Background: The rising prevalence of type II diabetes mellitus (T2DM) has increased the risk of hepatic dysfunction, necessitating effective therapeutic interventions. Natural products, particularly (BA) and (WS), are known for their hepatoprotective properties.
Objectives: This study investigates the hepatoprotective effects of BA, WS, and their polyherbal combination in streptozotocin-nicotinamide-induced T2DM in Wistar rats.
BMC Infect Dis
March 2025
Department of Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.
The global pandemic of novel coronavirus pneumonia (COVID-19) has resulted in millions of deaths over the past three years. As one of the most commonly affected extra-pulmonary organs, numerous studies have reported varying degrees of liver injury in a significant proportion of patients with COVID-19, particularly in severe and critically ill patients. Early prediction of liver dysfunction in hospitalized patients would facilitate the clinical management of COVID-19 and improve clinical prognosis, but reliable and valid predictive models are still lacking.
View Article and Find Full Text PDFCommun Biol
March 2025
National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Acute pancreatitis can lead to systemic inflammation and multiple organ damage. Increased endothelial permeability is a hallmark of systemic inflammation. Several studies have demonstrated that cold-inducible RNA-binding protein (CIRP) functions as a proinflammatory factor in various diseases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!